Anthracycline vs Nonanthracycline Adjuvant Therapy for Breast Cancer
October 01, 2004
The authors present a comprehensivereview of anthracycline-based adjuvant chemotherapyregimens, supporting the useof these regimens over CMF (cyclophosphamide[Cytoxan, Neosar],methotrexate, fluorouracil [5-FU]) inearly-stage breast cancer. They concludethat the addition of taxanes toanthracycline-containing regimens innode-positive disease may conferadditional benefit. Newer regimenscontaining taxanes and other agentsthat omit the use of anthracyclinesshow promise but are still underinvestigation.